XML 61 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated income statements - EUR (€)
€ in Millions, shares in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
 [1]
Dec. 31, 2022
Profit (loss) [abstract]      
Net sales € 41,081 € 37,817 € 37,651 [1]
Other revenues 3,205 3,801 [2] 2,910 [1],[2]
Cost of sales (13,205) (12,628) (11,882) [1]
Gross profit 31,081 28,990 28,679 [1]
Research and development expenses (7,394) (6,507) (6,501) [1]
Selling and general expenses (9,183) (8,933) (8,739) [1]
Other operating income 1,089 979 1,814 [1]
Other operating expenses (4,382) (3,443) (2,523) [1]
Amortization of intangible assets (1,749) (1,911) (1,804) [1]
Impairment of intangible assets (248) (896) 429 [1]
Fair value remeasurement of contingent consideration (96) (93) 27 [1]
Restructuring costs and similar items (1,396) (1,030) [3] (1,077) [1],[3]
Other gains and losses, and litigation (470) (196) (143) [1]
Operating income 7,252 6,960 [4] 10,162 [1],[4],[5]
Financial expenses (1,073) (1,293) [4],[6] (430) [1],[4],[5],[6]
Financial income 519 584 [4],[6] 205 [1],[4],[5],[6]
Income before tax and investments accounted for using the equity method 6,698 6,251 [4],[7] 9,937 [1],[4],[5],[7]
Income tax expense (1,204) (1,017) [7] (1,909) [1],[7]
Share of profit/(loss) from investments accounted for using the equity method 60 (136) 55 [1]
Net income from continuing operations 5,554 5,098 8,083 [1]
Net income excluding the exchanged/held-for-exchange Animal Health business 64 338 401 [1]
Net income 5,618 5,436 8,484 [1]
Net income attributable to non-controlling interests 58 36 [8] 113 [1],[8]
Net income attributable to equity holders of Sanofi € 5,560 € 5,400 € 8,371 [1]
Average number of shares outstanding (in shares) 1,251.4 1,251.7 1,251.9 [1]
Average number of shares after dilution (in shares) 1,256.1 1,256.4 1,256.9
Basic earnings per share excluding the exchanged/held-for-exchange Animal Health business (in euros per share) € 4.40 € 4.06 € 6.38 [1]
Diluted earnings per share (in euros per share) 4.39 4.05 6.35 [1]
Basic earnings (loss) per share from discontinued operations 0.04 0.25 0.31 [1]
Basic earnings (loss) per share 4.44 4.31 6.69 [1]
Diluted earnings (loss) per share from discontinued operations 0.04 0.25 0.31 [1]
Diluted earnings (loss) per share € 4.43 € 4.30 € 6.66 [1]
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[3] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[4] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[5] 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€706 million net of tax)
[6] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[7] (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[8] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations).